US 11,986,445 B2
Nutritional composition and infant formula for promoting myelination of the brain
Nora Schneider, Epalinges (CH); Jonas Hauser, Lausanne (CH); Sean Deoni, Providence, RI (US); and Tamas Bartfai, Stockholm (SE)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Appl. No. 16/061,063
Filed by SOCIÉTÉ DES PRODUITS NESTLÉ S.A., Vevey (CH)
PCT Filed Dec. 13, 2016, PCT No. PCT/EP2016/080772
§ 371(c)(1), (2) Date Jun. 11, 2018,
PCT Pub. No. WO2017/102712, PCT Pub. Date Jun. 22, 2017.
Claims priority of provisional application 62/328,062, filed on Apr. 27, 2016.
Claims priority of provisional application 62/315,224, filed on Mar. 30, 2016.
Claims priority of provisional application 62/315,187, filed on Mar. 30, 2016.
Claims priority of provisional application 62/315,238, filed on Mar. 30, 2016.
Claims priority of provisional application 62/315,249, filed on Mar. 30, 2016.
Claims priority of provisional application 62/315,198, filed on Mar. 30, 2016.
Claims priority of application No. 15199752 (EP), filed on Dec. 14, 2015; application No. 15199757 (EP), filed on Dec. 14, 2015; application No. 15199758 (EP), filed on Dec. 14, 2015; application No. 15199764 (EP), filed on Dec. 14, 2015; and application No. 15199769 (EP), filed on Dec. 14, 2015.
Prior Publication US 2019/0254994 A1, Aug. 22, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/14 (2006.01); A23L 33/00 (2016.01); A23L 33/10 (2016.01); A23L 33/12 (2016.01); A23L 33/15 (2016.01); A23L 33/16 (2016.01); A61K 31/20 (2006.01); A61K 31/201 (2006.01); A61K 31/202 (2006.01); A61K 31/519 (2006.01); A61K 31/683 (2006.01); A61K 31/685 (2006.01); A61K 31/688 (2006.01); A61K 31/714 (2006.01); A61K 33/06 (2006.01); A61K 33/26 (2006.01); A61K 33/30 (2006.01); A61P 3/02 (2006.01)
CPC A61K 31/14 (2013.01) [A23L 33/10 (2016.08); A23L 33/12 (2016.08); A23L 33/15 (2016.08); A23L 33/16 (2016.08); A23L 33/30 (2016.08); A23L 33/40 (2016.08); A61K 31/20 (2013.01); A61K 31/201 (2013.01); A61K 31/202 (2013.01); A61K 31/519 (2013.01); A61K 31/683 (2013.01); A61K 31/685 (2013.01); A61K 31/688 (2013.01); A61K 31/714 (2013.01); A61K 33/06 (2013.01); A61K 33/26 (2013.01); A61K 33/30 (2013.01); A61P 3/02 (2018.01); A23V 2002/00 (2013.01)] 9 Claims
 
1. A method to promote, support or optimize de novo myelination including de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a formula fed infant up to 12 months of age in need thereof, the method comprising administering a synthetic nutritional composition comprising choline to the formula fed infant up to 12 months of age,
wherein the synthetic nutritional composition comprises the choline in an amount greater than 30 mg/100 g dry weight of the synthetic nutritional composition,
the brain structure refers to an amount and/or spatial distribution of myelinated matter throughout the brain and/or in specific brain regions, and the cognitive functioning is optimized if scores of the formula fed infant up to 12 months of age in a standardized neurodevelopmental test are less than one standard deviation different from that of an exclusively breastfed infant up to 12 months of age of a well-nourished mother, and
the synthetic nutritional composition further comprises iron; a fatty acid derivative comprising at least one of docosahexaenoic acid or arachidonic acid; and a phospholipid selected from the group consisting of phosphatidylcholine, phosphatidylinositole, phosphatidylserine, phosphatidylethanolamine, and sphingomyelin, and mixtures thereof.